Kedrion Biopharma announces the execution of a binding memorandum of understanding with Kamada Ltd., an Israeli commercial stage global biopharmaceutical company and leader in the specialty plasma-derived field, for the amendment and the 8-year extension of the KEDRAB® US distribution agreement between the two companies.
This Human Rabies Immune Globulin (HRIG) has been developed in partnership with Kamada Ltd. Kedrion started the distribution of this product in the US in 2018. The new commercial agreement, which begins in January 2024, includes potential expansion of Kedrion’s distribution of the product into additional territories beyond the US. In addition, the two companies will collaborate to expand distribution of Kedrion products by Kamada in Israel.
Ugo Di Francesco, CEO of Kedrion, said “This agreement marks another relevant milestone in the grow of Kedrion in the US, which remains our most important market. At Kedrion, we firmly believe in the power of our long-term partnership with Kamada to help people who have been exposed to Rabies. This agreement will allow us to continue to serve patients in the US, leveraging the expertise and the extensive know-how we have acquired over the years. Kedrion’s commitment to providing relief from conditions requiring hyperimmune plasma-derived therapies remains strong.”
“We are thrilled to secure this strategic agreement with Kedrion as it represents our largest commercial agreement since Kamada’s inception,” said Amir London, CEO of Kamada. “Based on Kedrion’s extensive market coverage and on-going success in marketing Human Rabies Immune Globulin in the US, as well as the significant market share growth achieved to date, we are confident that the continuation of this partnership maximizes the future growth and value potential of this important product.”
Rabies is a serious and life-threatening disease but is easily preventable. It is contracted from the bite of a rabid wild animal – primarily bats, raccoons, skunks and foxes – as well as rabid pets.
Still today, Rabies is a global public threat that causes more than 59,000 human deaths per year in the world. PEP treatment is administered an estimated 60,000 per year each year in the United States.
